Keros Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 75.63 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 10.50K shares, a 90.03% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 65.13K shares, a 72.40% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 17.05K shares, a 16.82% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 623.33K shares, a 3658.83% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 783.50K shares, a 244.00% increase from fiscal 2024.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 227.76K shares, a 11.79% decline from fiscal 2023.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 258.21K shares, a 32.13% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 195.43K shares, a 11.05% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 10.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 75.63K shares 10-Q · filed 2026-08-03 | 92.68K shares derived: sum of 3 quarters · filed 2026-08-03 | 716.00K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 65.13K shares 10-Q · filed 2026-05-14 | 82.18K shares derived: sum of 2 quarters · filed 2026-05-14 | 705.50K shares derived: sum of 3 quarters · filed 2026-05-14 | 810.84K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 17.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | 640.38K shares derived: sum of 2 quarters · filed 2026-03-04 | 745.72K shares derived: sum of 3 quarters · filed 2026-03-04 | 783.50K shares 10-K · filed 2026-03-04 |
| 2025-09-30 | 623.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 728.67K shares derived: sum of 2 quarters · filed 2025-11-05 | 766.44K shares 10-Q · filed 2025-11-05 | 786.94K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 105.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 143.12K shares 10-Q · filed 2025-08-06 | 163.62K shares derived: sum of 3 quarters · filed 2025-08-06 | 180.20K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 37.78K shares 10-Q · filed 2025-05-06 | 58.28K shares derived: sum of 2 quarters · filed 2025-05-06 | 74.86K shares derived: sum of 3 quarters · filed 2025-05-06 | 127.44K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 20.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 37.08K shares derived: sum of 2 quarters · filed 2025-02-26 | 89.66K shares derived: sum of 3 quarters · filed 2025-02-26 | 227.76K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 16.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 69.16K shares derived: sum of 2 quarters · filed 2024-11-06 | 207.26K shares 10-Q · filed 2024-11-06 | 232.07K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 52.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 190.68K shares 10-Q · filed 2024-08-07 | 215.49K shares derived: sum of 3 quarters · filed 2024-08-07 | 340.24K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 138.10K shares 10-Q · filed 2024-05-08 | 162.91K shares derived: sum of 2 quarters · filed 2024-05-08 | 287.66K shares derived: sum of 3 quarters · filed 2024-05-08 | 341.17K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 24.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 149.56K shares derived: sum of 2 quarters · filed 2024-02-28 | 203.07K shares derived: sum of 3 quarters · filed 2024-02-28 | 258.21K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 124.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 178.26K shares derived: sum of 2 quarters · filed 2023-11-06 | 233.40K shares 10-Q · filed 2023-11-06 | 262.31K shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 53.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 108.65K shares 10-Q · filed 2023-08-07 | 137.56K shares derived: sum of 3 quarters · filed 2023-08-07 | 219.39K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 55.14K shares 10-Q · filed 2023-05-04 | 84.05K shares derived: sum of 2 quarters · filed 2023-05-04 | 165.88K shares derived: sum of 3 quarters · filed 2023-05-04 | |
| 2022-12-31 | 28.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | 110.74K shares derived: sum of 2 quarters · filed 2023-03-03 | 195.43K shares 10-K · filed 2023-03-03 | |
| 2022-09-30 | 81.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 166.52K shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 84.69K shares 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | 175.98K shares 10-K · filed 2022-03-09 | |||
| 2020-12-31 | 3.03K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |